Endometrial Cancer Clinical Trials in Little Rock, Arkansas

7 studies are recruiting for endometrial cancer in Little Rock, Arkansas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

   This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody , in participants with platinum-refractory/resistant ovarian cancer (PRROC) and other advanced CLDN6-positive soli…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Arkansas Winthrop P. Rockefeller Cancer Institute, Little Rock, Arkansas

   Locations

   15 in total

   Run by

   Context Therapeutics Inc.

   See if you can join NCT06515613 on ClinicalTrials.gov

2. DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

   DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participant…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Little Rock, Arkansas

   Locations

   255 in total

   Run by

   AstraZeneca

   See if you can join NCT06989112 on ClinicalTrials.gov

3. A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

   HWK-016-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-016, a targeted antibody-drug conjugate (ADC) in adult participants with advanced or metastatic solid tumors. The study employs a dose escalation and dose expansion design without a control group. The study …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Arkansas - Winthrop P. Rockefeller Cancer Institute, Little Rock, Arkansas

   Locations

   12 in total

   Run by

   Whitehawk Therapeutics, Inc.

   See if you can join NCT07470853 on ClinicalTrials.gov

4. Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

   HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conjugate (ADC), in adult participants with advanced or metastatic solid tumors known to be expressing PTK7. The study employs a sequential dose…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Arkansas, Little Rock, Arkansas

   Locations

   12 in total

   Run by

   Whitehawk Therapeutics, Inc.

   See if you can join NCT07444814 on ClinicalTrials.gov

5. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

   This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Arkansas - Winthrop P. Rockefeller Cancer Institute, Little Rock, Arkansas

   Locations

   82 in total

   Run by

   Artios Pharma Ltd

   See if you can join NCT04657068 on ClinicalTrials.gov

6. Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer

   A Phase 2 Multi-center Open-label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Michael Birrer, MD, PhD, Little Rock, Arkansas

   Locations

   9 in total

   Run by

   Aadi Bioscience, Inc.

   See if you can join NCT05997017 on ClinicalTrials.gov

7. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

   International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

   Stage

   Not phased

   Ages

   Any age

   Site

   Massive Bio SYNERGY-AI site, Little Rock, Arkansas

   Locations

   68 in total

   Run by

   Massive Bio, Inc.

   See if you can join NCT03452774 on ClinicalTrials.gov